Bipolar Disorders Treatment Market Research Report: Information by Drug Type (Mood Stabilizer, Anticonvulsant, Antipsychotic Drug, and Antidepressant Drug), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Monoamine Oxidase Inhibitors, Beta Blockers, and Tricyclic Antidepressant Drug), End User (Hospitals and Clinics, Multispecialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2027
ID: MRFR/Pharma/1037-HCR | February 2021 | Region: Global | 85 Pages
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
Chapter 6. Global Bipolar Disorders Treatment Market, by Drug Type
6.1 Introduction
6.2 Mood Stabilizer
6.3 Anticonvulsant
6.4 Antipsychotic Drug
6.5 Antidepressant Drug
6.6 Other
Chapter 7. Global Bipolar Disorders Treatment Market, by Mechanism of Action
7.1 Introduction
7.2 Selective Serotonin Reuptake Inhibitor
7.3 Serotonin Norepinephrine Reuptake Inhibitor
7.4 Monoamine Oxidase Inhibitors
7.5 Beta Blockers
7.6 Tricyclic Antidepressant Drug
7.7 Others
Chapter 8. Global Bipolar Disorders and Treatment Market, by End User
8.1 Introduction
8.2 Hospitals and Clinics
8.3 Multispecialty Centers
8.4 Others
Chapter 9. Global Bipolar Disorders Treatment Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 Latin America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Allergan
11.1.1 Company Overview
11.1.2 Drug Type Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 Baxter International, Inc.
11.2.1 Company Overview
11.2.2 Drug Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 AstraZeneca
11.3.1 Company Overview
11.3.2 Drug Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Eli Lilly and Company
11.4.1 Company Overview
11.4.2 Technologys/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 GlaxoSmithKline
11.5.1 Company Overview
11.5.2 Drug Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Abbott
11.6.1 Company Overview
11.6.2 Drug Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Bristol-Myers Squibb
11.7.1 Overview
11.7.2 Drug Type Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Johnson & Johnson
11.8.1 Overview
11.8.2 Drug Type/ Technology Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Pfizer Inc.
11.9.1 Overview
11.9.2 Drug Type Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Cephalon Inc.
11.10.1 Overview
11.10.2 Drug Type Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Otsuka America Pharmaceutical Inc.
11.11.1 Overview
11.11.2 Drug Type Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Gedeon Richter plc
11.12.1 Overview
11.12.2 Drug Type Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 Others
Chapter 12. Appendix
LIST OF TABLES
Table 1 Global Bipolar Disorders Treatment Synopsis, 2020-2027
Table 2 Global Bipolar Disorders Treatment Market Estimates and Forecast, 2020-2027, (USD Million)
Table 3 Global Bipolar Disorders Treatment Market, by Region 2020-2027, (USD Million)
Table 4 Global Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 5 Global Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 6 Global Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 7 North America: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 8 North America: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 9 North America: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 10 US: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 11 US: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 12 US: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 13 Canada: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 14 Canada: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 15 Canada: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 16 Latin America: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 17 Latin America: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 18 Latin America: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 19 Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 20 Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 21 Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 22 Western Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 23 Western Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 24 Western Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 25 Eastern Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 26 Eastern Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 27 Eastern Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 28 Asia-Pacific: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 29 Asia-Pacific: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 30 Asia-Pacific: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
Table 31 Middle East & Africa: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)
Table 32 Middle East & Africa: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)
Table 33 Middle East & Africa: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation of the Global Bipolar Disorders Treatment Market
Figure 3 Segmentation Market Dynamics for the Global Bipolar Disorders Treatment Market
Figure 4 Global Bipolar Disorders Treatment Market Share, by Drug Type, 2020
Figure 5 Global Bipolar Disorders Treatment Market Share, by Mechanism of Action, 2020
Figure 6 Global Bipolar Disorders Treatment Market Share, by End User, 2020
Figure 7 Global Bipolar Disorders Treatment Market Share, by Region, 2020
Figure 8 North America: Bipolar Disorders Treatment Market Share, by Country, 2020
Figure 9 Europe: Bipolar Disorders Treatment Market Share, by Country, 2020
Figure 10 Asia-Pacific: Bipolar Disorders Treatment Market Share, by Country, 2020
Figure 11 Middle East & Africa: Bipolar Disorders Treatment Market Share, by Country, 2020
Figure 12 Global Bipolar Disorders Treatment Market: Company Share Analysis, 2020 (%)
Figure 13 Allergan: Key Financials
Figure 14 Allergan: Segmental Revenue
Figure 15 Allergan: Geographical Revenue
Figure 16 Baxter International, Inc.: Key Financials
Figure 17 Baxter International, Inc.: Segmental Revenue
Figure 18 Baxter International, Inc.: Geographical Revenue
Figure 19 AstraZeneca: Key Financials
Figure 20 AstraZeneca.: Segmental Revenue
Figure 21 AstraZeneca: Geographical Revenue
Figure 22 Eli Lilly and Company.: Key Financials
Figure 23 Eli Lilly and Company: Segmental Revenue
Figure 24 Eli Lilly and Company: Geographical Revenue
Figure 25 GlaxoSmithKline: Key Financials
Figure 26 GlaxoSmithKline: Segmental Revenue
Figure 27 GlaxoSmithKline: Geographical Revenue
Figure 28 Abbott: Key Financials
Figure 29 Abbott: Segmental Revenue
Figure 30 Abbott: Geographical Revenue
Figure 31 Bristol-Myers Squibb: Key Financials
Figure 32 Bristol-Myers Squibb: Segmental Revenue
Figure 33 Bristol-Myers Squibb: Geographical Revenue
Figure 34 Johnson & Johnson: Key Financials
Figure 35 Johnson & Johnson: Segmental Revenue
Figure 36 Johnson & Johnson: Geographical Revenue
Figure 37 Pfizer Inc.: Key Financials
Figure 38 Pfizer Inc.: Segmental Revenue
Figure 39 Pfizer Inc.: Geographical Revenue
Figure 40 Cephalon Inc.: Key Financials
Figure 41 Cephalon Inc.: Segmental Revenue
Figure 42 Cephalon Inc.: Geographical Revenue
Figure 43 Otsuka America Pharmaceutical Inc.: Key Financials
Figure 44 Otsuka America Pharmaceutical Inc.: Segmental Revenue
Figure 45 Otsuka America Pharmaceutical Inc.: Geographical Revenue
Figure 46 Gedeon Richter plc: Key Financials
Figure 47 Gedeon Richter plc: Segmental Revenue
Figure 48 Gedeon Richter plc: Geographical Revenue
Bipolar Disorders Treatment Market
Bipolar Disorders Treatment Market size is expected to register a CAGR of 2.9% and was valued at USD 5600 Million.
$5600 Million
Market Size
2.9%%
CAGR
North America
Dominating Region
2020-2027
Forecast Period
Segmentation
Key Players
- Allergan (Ireland)
- AstraZeneca (UK)
- Eli Lilly and Company(US)
- GlaxoSmithKline(UK)
- Abbott (US)
- Bristol-Myers Squibb (US)
- Johnson & Johnson (US)
- Pfizer Inc. (US)
- Cephalon Inc. (US)
- Otsuka America Pharmaceutical Inc. (US)
- and Gedeon Richter plc (Hungary)
Drivers
- government initiatives for treatment of bipolar disorders
- advancement in combination drugs
Bipolar Disorders Treatment Market Scenario
The bipolar disorders treatment market is expected to grow significantly over the forecast period. The global market was valued at USD 5600 million in 2018 and is projected to grow with 2.9% CAGR over the forecast period (2019-2025). Bipolar disorder is a manic-depressive disorder, which is a type of mental illness. It is characterized by mood swings and mood episodes appear during the illness. Manic and depressive episodes are common mood episodes observed in bipolar disorders. The government initiatives for treatment of bipolar disorders, advancement in combination drugs, and growing demand for antidepressant drugs are expected to drive the growth of the market. Moreover, growing research and development activities conducted by government and nonprofit organizations are contributing to the growth of the market. For instance, Harvard University started Harvard brain science initiative (HBI) for R&D on bipolar disorders. This program has provided USD 3 million in funds to the research and development related to bipolar disorders. The side effects associated with therapy, low diagnosis rate, and dearth of experts may hamper the growth of the global market during the assessment period.
Segmentation
The global bipolar disorders and treatment market has been segmented on the basis of drug class, mechanism of action, and end user. Based on drug type, the global market has been classified into mood stabilizer, antipsychotic drugs, antianxiety drugs, antidepressant drugs, anticonvulsants, and others. Based on the mechanism of action, the global market has been segmented into selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitors, beta-blockers, tricyclic antidepressant drug, and others. The global market, by end user, has been segmented into hospitals and clinics, multispecialty centers, and others. The bipolar disorders treatment market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European market has been bifurcated into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bipolar disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary) are some of the key players operating in the bipolar disorders treatment market.
Regional Market Summary Global Bipolar Disorders Treatment Market Share (%), by Region, 2018 
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are likely to dominate the global bipolar disorders and treatment market owing to technological advancement, presence of major players in the region, well-established healthcare system, and increasing cases of bipolar disorders in the region. According to the National Institute of Mental Health (NIMH), approximately 3% of adults in the US were suffering from bipolar disorders in 2016 and this percentage is expected to increase significantly in the future due to changing lifestyles.
The European market is expected to be the second-largest bipolar disorders and treatment market. The market growth in this region can be attributed to the increasing number of mental disorders, increasing government funding for treatment of bipolar disorders, and growing research and development activities related to mental health. For instance, in November 2017, Mental Health UK launched a partnership with Lloyds Banking Group to help bipolar disorder patients and to manage and improve their financial and mental health. Asia-Pacific is expected to be the fastest-growing bipolar disorders and treatment market during the forecast period owing to the increasing prevalence of genetic disorders, growing awareness about bipolar disorders, and rising investment by major players in the region. According to the Black Dog Institute, bipolar disorder is related with the genetic condition of an individual, if the parents are suffering from bipolar disorder it is more than 10% likely that their children will experience the same condition in future. The Middle East & Africa is expected to account for the smallest share of the bipolar disorders treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Bipolar disorders treatment market, by Drug Type
- Mood Stabilizer
- Antipsychotic Drugs
- Antianxiety Drugs
- Antidepressant drugs
- Anticonvulsants
- Others
Bipolar disorders treatment market, by Mechanism of Action
- Selective Serotonin Reuptake Inhibitor
- Serotonin Norepinephrine Reuptake Inhibitor
- Monoamine Oxidase Inhibitors
- Beta-Blockers
- Tricyclic Antidepressant Drug
- Others
Bipolar disorders treatment market, by End User
- Hospitals and Clinics
- Multispecialty Centres
- Others
Bipolar disorders treatment market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Bipolar disorders treatment market, by Key Players
- Allergan
- AstraZeneca
- Eli Lilly and Company
- GlaxoSmithKline
- Abbott
- Bristol-Myers Squibb
- Johnson & Johnson
- Pfizer Inc.
- Cephalon Inc.
- Otsuka America Pharmaceutical Inc.
- Gedeon Richter plc
- Others
Intended Audience
- Bipolar disorders and treatment centers
- Contract research organizations (CROs)
- Research and development (R&D) companies
- Government research laboratories
- Independent research laboratories
- Government and independent regulatory authorities
- Market research and consulting service providers
- Medical research laboratories
- Academic medical institutes and universities
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size |
|
| CAGR | 2.9% (2019–2025) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drug Type, Mechanism of Action and End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary) |
| Key Market Opportunities | side effects associated with therapy, low diagnosis rate, and dearth of experts |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
bipolar disorders treatment market was valued at USD 5.6 billion in 2018.
global market is expected to exhibit a strong 2.9% CAGR over the forecast period from 2019 to 2025.
The growing prevalence of bipolar disorders is the major driver for the market.
The Americas and Europe dominate the global bipolar disorder treatment market.
Leading players in the market include Allergan, AstraZeneca, and Pfizer, among others.
